Cardiovascular disease (CVD) remains the leading cause of mortality in developed countries. According to the 2012 European Guidelines on Cardiovascular Disease Prevention in Clinical Practice, family history is a cornerstone for risk stratification of CVD. First-degree relatives are persons in whom CVD should be assessed and targeted intervention should be performed. The aims of this pilot study were (i) to determine risk factors (RFs) for cardiovascular disease (CVD) in a group of first-degree relatives of patients with CVD at baseline and after 1 year, (ii) to measure adipocyte fatty acid-binding protein (A-FABP) levels as a potential connecting link between metabolic disease and atherosclerosis, and (iii) to determine the impact of targeted intervention on these parameters. The study comprised 62 asymptomatic subjects (41 males; mean age of 53.8±8.3 years). Preventive examinations and interventions were carried out at baseline and at 1-year follow-up to assess RFs and evaluate A-FABP levels. At 1 year, males had significantly lower levels of cholesterol (median 5.18 vs 4.67, p=0.005), HDL (median 1.24 vs 1.14, p=0.021), LDL (median 3.08 vs 2.46, p=0.021), ApoB (median 0.99 vs 0.82, p=0.012) and A-FABP (median 19.84 vs 16.73, p = 0.015). In females after 1 year, only significantly lower levels of fibrinogen (median 3.10 vs 2.79, p=0.043) were found. All subjects were clinically examined or contacted by phone after a mean of 36.7 months (range, 11–55). Over that time, no serious complications were noted. In males, intervention for RFs leads to lower levels of A-FABP as a potential RF linking metabolic syndrome to atherosclerosis.
If the inline PDF is not rendering correctly, you can download the PDF file here.
 De Backer G., Ambrosionie E., Borch-Johnsen K., Brotons C., Cifkova R., Dallongeville J., et al. European Guidelines on cardiovascular disease prevention in clinical practice (version 2012). http://www.escardio.org/guidelines-surveys/escguidelines/GuidelinesDocuments/guidelines-CVDprevention.pdf. 14.3.2013
 Graham I., Atar D., Borch-Johnsen K., Boysen G., Burell G., Cifkova R., et al., European guidelines on cardiovascular disease prevention in clinical practice: executive summary, EJCPR., 2007, 14, 1–113
 Kazemi M.R., McDonald C.M., Shigenaga J.K., Grunfeld C., Feingold K.R., Adipocyte fatty acid-binding protein expression and lipid accumulation are increased during activation of murine macrophages by toll-like receptor agonists. Arterioscler. Thromb. Vasc. Biol., 2005, 25, 1220–1224 http://dx.doi.org/10.1161/01.ATV.0000159163.52632.1b
 Erbay E., Cao H., Hotamisligil G.S. Adipocyte/macrophage fatty acid binding proteins in metabolic syndrome, Curr. Atheroscler. Rep., 2007, 9, 222–9. http://dx.doi.org/10.1007/s11883-007-0023-6
 Lam D.C., Xu A., Lam K.S. Serum adipocyte-fatty acid binding protein level is elevated in severe OSA and correlates with insulin resistance, Eur. Respir. J., 2009, 33, 346–351 http://dx.doi.org/10.1183/09031936.50075408
 Tuncman G., Erbay E., Hom X., De Vivo I., Campos H., Rimm E.B., et al., A genetic variant at the fatty acid binding protein aP2 locus reduces the risk for hypertriglyceridemia, type 2 diabetes, and cardiovascular disease, Proc. Natl. Acad. Sci. USA., 2005, 103, 6970–6975 http://dx.doi.org/10.1073/pnas.0602178103
 Tso A.W.K., Xu A., Sham P.C., Wat N.M.S, Wang Y, Fong C.H.Y., et al., Serum adipocyte fatty acidbinding protein as a new biomarker predicting the development of type 2 diabetes: A 10-year prospective study in a Chinese cohort, Diabetes Care., 2007, 30, 2667–2672 http://dx.doi.org/10.2337/dc07-0413
 Miyoshi T., Onoue G., Hirohata A., Hirohata S., Usui S., Hina K., et al., Serum adipocyte fatty acid-binding protein is independently associated with coronary atherosclerotic burden measured by intravascular ultrasound, Atherosclerosis, 2010, 211, 164–169 http://dx.doi.org/10.1016/j.atherosclerosis.2010.01.032
 Rhee E.J., Lee W.Y., Park CY. The association of serum adipocyte fatty acid-binding protein with coronary artery disease in Korean adults, Eur. J. Endocrinol., 2009, 160, 165–172 http://dx.doi.org/10.1530/EJE-08-0665
 Krusinova E., Pelikanova T., Fatty acid binding proteins in adipose tissue: A promising link between metabolic syndrome and atherosclerosis?, Diabetes Research and Clinical Practice, 2008, 82, 127–134 http://dx.doi.org/10.1016/j.diabres.2008.09.023
 Stejskal D., Karpíšek M., Adipocyte fatty acid binding protein in a Caucasian population: a new marker of metabolic syndrome?, Eur. J. Clin. Invest., 2006, 36, 621–625 http://dx.doi.org/10.1111/j.1365-2362.2006.01696.x
 Karpisek M., Stejskal D., Kotolova H., Kollar P., Janoutova G., Ochmanova R., et al., Treatment with atorvastatin reduces serum adipocyte-fatty acid binding protein value in patients with hyperlipidemia, Eur. J. Clin. Invest., 2007, 37, 637–642 http://dx.doi.org/10.1111/j.1365-2362.2007.01835.x
 Makowski L., Brittingham K.C., Reynolds J.M., Sutles J., Hotamisligil G.S., The fatty acid-binding protein, aP2, coordinates macrophage cholesterol trafficking and inflammatory activity. Macrophage expression of aP2 impacts peroxisome proliferator-activated receptor gamma and IkappaB kinase activities, J. Biol. Chem., 2005, 280, 12888–12895 http://dx.doi.org/10.1074/jbc.M413788200
 Peeters W., de Kleijn D.P.V, Vink A., de Weg S., Schoneveld A.H., Ste S.K, et al., Adipocyte fatty acid binding protein in atherosclerotic plaques is associated with local vulnerability and is predictive for the occurrence of adverse cardiovascular events, Eur. Heart J., 2011, 32, 1758–1768 http://dx.doi.org/10.1093/eurheartj/ehq387
 Doi M., Miyoshi T., Hirohata S., Nakamura K., Usui S., Takeda K, et al., Association of increased plasma adipocyte fatty acid-binding protein with coronary artery disease in non-elderly men, Cardiovasc. Diabetol., 2011, 10, 44 http://dx.doi.org/10.1186/1475-2840-10-44
 Sovova E., Vrbkova J., Stejskal D., Kaletova M., Kaminek M., Metelkova I., Sova M., Benusova I., Doupalova P., Is there dependence between the level of adipocyte fatty acid-binding protein and calcium score in asymptomatic relatives of patients with cardiovascular diseases?, Vnitrni lekarstvi, 2013, 59(1), 31–36
 Mosca L., Mochari H., Liao M., Christian A.H., Edelman D.J., Aggarwal B., et al., A novel family-based intervention trial to improve heart health: FIT Heart: results of a randomized controlled trial, Circ. Cardiovasc. Qual. Outcomes, 2008, 1, 98–106 http://dx.doi.org/10.1161/CIRCOUTCOMES.108.825786
 Naslindh-Ylispangar A., Sihvonen M., Sarna S., Vanhanen H., Kekki P., Has brief counseling an impact on the risk factors for cardiovascular disease in 40-year-old me. A three year follow-up study, Cent. Eur. J. Med., 2008, 3, 300–307 http://dx.doi.org/10.2478/s11536-008-0034-x
 Bertuzzi M., Negri E., Tavani A., La Vecchia C., Family history of ischemic heart disease and risk of acute myocardial infarction, Prev. Med., 2003, 37, 183–187 http://dx.doi.org/10.1016/S0091-7435(03)00094-X
 Janssens A.C., Wilde A.A., van Langen I.M., The sense and nonsense of direct-to-consumer genetic testing for cardiovascular disease, Neth. Heart. J., 2011, 19, 85–88 http://dx.doi.org/10.1007/s12471-010-0069-x
Open Medicine is an open access journal that provides users with free, instant, and continued access to all content worldwide. The journal aims to promote knowledge that is directly relevant to all fields of Medical Science.